Compare XELB & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XELB | CVKD |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.3M |
| IPO Year | 2011 | 2022 |
| Metric | XELB | CVKD |
|---|---|---|
| Price | $1.42 | $2.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 75.6K | 71.1K |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.37 | 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $2.29 |
| 52 Week High | $2.66 | $14.64 |
| Indicator | XELB | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 33.58 | 29.23 |
| Support Level | $1.25 | N/A |
| Resistance Level | $1.62 | $3.89 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 2.30 | 4.79 |
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.